KR102717921B1 - 심혈관 효과가 감소된 피임약 조성물 - Google Patents

심혈관 효과가 감소된 피임약 조성물 Download PDF

Info

Publication number
KR102717921B1
KR102717921B1 KR1020207025456A KR20207025456A KR102717921B1 KR 102717921 B1 KR102717921 B1 KR 102717921B1 KR 1020207025456 A KR1020207025456 A KR 1020207025456A KR 20207025456 A KR20207025456 A KR 20207025456A KR 102717921 B1 KR102717921 B1 KR 102717921B1
Authority
KR
South Korea
Prior art keywords
risk
estetrol
vte
paragraph
drospirenone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207025456A
Other languages
English (en)
Korean (ko)
Other versions
KR20200118464A (ko
Inventor
마우드 조스트
글웨디스 라우신
Original Assignee
에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 filed Critical 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼
Publication of KR20200118464A publication Critical patent/KR20200118464A/ko
Application granted granted Critical
Publication of KR102717921B1 publication Critical patent/KR102717921B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
KR1020207025456A 2018-02-07 2019-02-07 심혈관 효과가 감소된 피임약 조성물 Active KR102717921B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18155571 2018-02-07
EP18155571.5 2018-02-07
EP18160586 2018-03-07
EP18160586.6 2018-03-07
PCT/EP2019/052980 WO2019154899A1 (en) 2018-02-07 2019-02-07 Contraceptive composition with reduced cardiovascular effects

Publications (2)

Publication Number Publication Date
KR20200118464A KR20200118464A (ko) 2020-10-15
KR102717921B1 true KR102717921B1 (ko) 2024-10-16

Family

ID=65278388

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207025456A Active KR102717921B1 (ko) 2018-02-07 2019-02-07 심혈관 효과가 감소된 피임약 조성물

Country Status (20)

Country Link
EP (2) EP4140489A1 (https=)
JP (2) JP2021513507A (https=)
KR (1) KR102717921B1 (https=)
CN (2) CN115429806A (https=)
AU (1) AU2019219070B2 (https=)
CA (2) CA3178181A1 (https=)
CL (1) CL2020002017A1 (https=)
EC (1) ECSP20054822A (https=)
GE (2) GEAP202215414A (https=)
IL (1) IL276584B2 (https=)
JO (1) JOP20200169A1 (https=)
MA (1) MA51733A (https=)
NZ (1) NZ766027A (https=)
PH (1) PH12020500601A1 (https=)
PY (1) PY1908892A (https=)
SG (1) SG11202007163WA (https=)
TW (1) TWI845496B (https=)
UA (1) UA126746C2 (https=)
UY (1) UY38075A (https=)
WO (1) WO2019154899A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3701944T3 (da) 2015-06-18 2022-03-14 Estetra Srl Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
LT3310346T (lt) 2015-06-18 2021-06-10 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
LT3310345T (lt) 2015-06-18 2021-06-25 Estetra Sprl Burnoje disperguojama tabletė, turinti estetrolio
CR20180042A (es) 2015-06-18 2018-05-03 Mithra Pharmaceuticals S A Unidad de dosificación orodispersable que contiene un componente estetrol.
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
CN111989105B (zh) 2018-04-19 2024-07-19 埃斯特拉私人有限责任公司 化合物以及它们在缓解绝经相关症状中的用途
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TWI893101B (zh) * 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
WO2022248733A1 (en) 2021-05-28 2022-12-01 Neuralis Sa Use of estetrol in treatment of respiratory infection diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
EP1390042B1 (en) * 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
CA2762640A1 (en) * 2009-05-22 2010-11-25 Stefanie Lindemann Medication for oral administration, comprising at least one estrogen and/or at least one gestagen and at least one probiotic bacterial strain
WO2012055840A1 (en) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
JP6447931B2 (ja) * 2013-12-12 2019-01-09 ドネスタ バイオサイエンス ビー.ブイ.Donesta Bioscience B.V. エステトロール成分を含有する口腔内崩壊固体単位剤形
CA3041016C (en) 2016-10-28 2023-09-05 Estetra Sprl Method for the management of dysmenorrhea and menstrual pain
KR102712911B1 (ko) * 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Contraception 95 (2017) 140-147*

Also Published As

Publication number Publication date
JP2024009834A (ja) 2024-01-23
CN111683664A (zh) 2020-09-18
JOP20200169A1 (ar) 2020-07-07
IL276584B2 (en) 2024-10-01
CA3178181A1 (en) 2019-08-15
IL276584B1 (en) 2024-06-01
EP3749327A1 (en) 2020-12-16
AU2019219070B2 (en) 2024-12-19
TW202011967A (zh) 2020-04-01
SG11202007163WA (en) 2020-08-28
GEAP202215414A (en) 2022-04-25
ECSP20054822A (es) 2020-12-31
AU2019219070A1 (en) 2020-09-24
IL276584A (en) 2020-09-30
JP7651645B2 (ja) 2025-03-26
NZ766027A (en) 2026-03-27
GEP20227407B (en) 2022-08-25
PH12020500601A1 (en) 2021-05-17
CN115429806A (zh) 2022-12-06
WO2019154899A1 (en) 2019-08-15
KR20200118464A (ko) 2020-10-15
CA3089804A1 (en) 2019-08-15
UY38075A (es) 2019-10-01
MA51733A (fr) 2020-12-16
CL2020002017A1 (es) 2020-12-04
EP4140489A1 (en) 2023-03-01
PY1908892A (es) 2019-10-15
TWI845496B (zh) 2024-06-21
JP2021513507A (ja) 2021-05-27
UA126746C2 (uk) 2023-01-18

Similar Documents

Publication Publication Date Title
KR102717921B1 (ko) 심혈관 효과가 감소된 피임약 조성물
US20250360147A1 (en) Methods using combined oral contraceptive compositions with reduced cardiovascular effects
US11896602B2 (en) Method for preventing pregnancy
Klipping et al. Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism
KR102780201B1 (ko) 월경통 및 생리통의 관리방법
Stanczyk et al. Gestodene: a review of its pharmacology, potency and tolerability in combined contraceptive preparations
Zahradnik et al. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)—an open-label, prospective, noncontrolled, office-based Phase III study
EP1558265A1 (en) Cardiovascular protection using anti-aldosteronic progestins
US7786101B2 (en) Cardiovascular protection using anti-aldosteronic progestins
HK40081220A (en) Contraceptive composition with reduced cardiovascular effects
EA048171B1 (ru) Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы
EA048537B1 (ru) Композиция контрацептива со сниженными эффектами в отношении сердечно-сосудистой системы
Pallavee et al. Peripheral arterial disease in a female using high-dose combined oral contraceptive pills
Palshetkar et al. Tackling PCOS with Hormonal Contraceptives

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

D12-X000 Request for substantive examination rejected

St.27 status event code: A-1-2-D10-D12-exm-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601